2025-10-24 - Analysis Report
Okay, here's the analysis of Merck & Co. (MRK), presented in a report format with a focus on key data points and their implications.

**Report: Merck & Co. (MRK) Analysis**

**Company Overview:**

Merck & Co. Inc. is a global pharmaceutical company that offers health solutions through its prescription medicines, vaccines, biologic therapies, and animal health products.

**1. Performance vs. S&P 500 (VOO)**

*   **MRK Cumulative Return:** 3.54%
*   **VOO Cumulative Return:** 99.09%
*   **Relative Divergence:**
    *   **Current:** -96.8
    *   **Range:** Max: 23.9, Min: -103.9
    *   **Relative Position:** 5.6

**Analysis:** MRK has significantly underperformed the S&P 500 over the period considered, with a substantial negative divergence.  The relative position of 5.6 indicates that the current divergence is near the lower end of its historical range, suggesting significant underperformance relative to its own past trends as well.

**Alpha/Beta Analysis (Historical Rolling Windows):**

| Year       | CAGR   | MDD    | Alpha   | Beta   | Cap(B) |
| :----------- | :----- | :----- | :------ | :----- | :----- |
| 2015-2017  | 0.0%   | 77.7%  | -28.0%  | 0.0    | 133.4  |
| 2016-2018  | 36.0%  | 69.8%  | 21.0%   | 0.0    | 181.2  |
| 2017-2019  | 41.0%  | 69.8%  | 18.0%   | 0.2    | 215.7  |
| 2018-2020  | 16.0%  | 79.5%  | -8.0%   | 0.3    | 194.0  |
| 2019-2021  | 2.0%   | 79.5%  | -44.0%  | 0.7    | 190.5  |
| 2020-2022  | 15.0%  | 79.6%  | 16.0%   | 0.7    | 275.7  |
| 2021-2023  | 33.0%  | 79.6%  | 31.0%   | 0.3    | 270.9  |
| 2022-2024  | -4.0%  | 79.6%  | -25.0%  | 0.2    | 247.2  |
| 2023-2025  | -46.0% | 71.5%  | -109.0% | 1.9    | 217.8  |

**Analysis:** The table shows a mixed picture of MRK's performance over different 3-year periods. CAGR (Compound Annual Growth Rate) varies significantly, with recent periods showing negative growth.  MDD (Maximum Drawdown) is consistently high, indicating significant potential for losses. Alpha is often negative, particularly in recent years, suggesting underperformance relative to the market risk-adjusted. The beta is relatively low, and has been increasing in recent years.  This indicates that MRK has become more correlated with the market. The market cap is also decreasing in recent years.

**2. Recent Stock Price Movement**

*   **Current Price:** $87.62
*   **Last Market Data:** Price: $87.18, Previous Close: $87.61, Change: -$0.49
*   **5-Day Moving Average:** 85.35
*   **20-Day Moving Average:** 85.07
*   **60-Day Moving Average:** 83.47

**Analysis:** MRK's current price is slightly above all three moving averages (5-day, 20-day, and 60-day). This suggests a short-term upward trend. The recent negative price change, while small, should be monitored.

**3. Technical Indicators and Expected Return**

*   **Market Risk Indicator (MRI):** 0.9 (High Investment Recommended)
*   **RSI:** 37.72
*   **PPO:** -0.0091
*   **Hybrid Signal:** Cash_0%_Buy 100% of cash (35 shares - Very Safe - MRI:0.90) Monthly invest 0.8% of total investment ($1,000.00) (Cash Ratio: 0% on 2025-10-01)
*   **20-Day Relative Divergence Change:** -3.6 (Negative - Short-term Decline)
*   **Expected Return:** -121.3% (Long-Term, vs. S&P 500)

**Analysis:**

*   The MRI suggests a favorable environment for investment, despite other mixed signals.
*   The RSI is below 40, which is near the oversold range, implying a potential for a price rebound.
*   The PPO being negative suggests a potential downward trend, but the value is very close to zero.
*   The negative change in relative divergence over the past 20 days confirms the short-term downward trend.
*   The very negative expected return indicates a significant projected underperformance relative to the S&P 500 over the long term. This is a major concern.

**4. Recent News & Significant Events:**

*   **ShiftconnectorÂ® Helps Power Merck's Visual Factory:** Focuses on improving transparency and agility in Merck's supply chain.
*   **Earnings Expected to Grow:**  Zacks reports expectations of earnings growth for Merck.
*   **FDA Grants Priority Review for Keytruda Applications:** Positive news regarding Keytruda, a key drug for Merck.
*   **Merck to Present New Cardio-Pulmonary Data:**  Indicates ongoing innovation and development in these therapeutic areas.

**Analysis:** The recent news is generally positive.  The FDA priority review for Keytruda is a significant positive catalyst.  The focus on supply chain improvements and upcoming data presentations also suggest a forward-looking approach.

**4-2. Analyst Opinions**

*   **Consensus:** Buy (Mean: 2.00)
*   **Opinions:** 25
*   **Target Price:** Avg: 101.84 / High: 137.00 / Low: 82.00
*   **Recent Rating Changes:** (No changes provided)

**Analysis:**  Analyst consensus is generally positive, with a "Buy" rating and a significant average target price above the current price. The range of target prices is wide, however, indicating some uncertainty.

**5. Recent Earnings Analysis**

| Date       | EPS  | Revenue     |
| :---------- | :---- | :----------- |
| 2025-08-05 | 1.76 | 15.81 B$   |
| 2025-05-02 | 2.01 | 15.53 B$   |
| 2024-11-06 | 1.25 | 16.66 B$   |
| 2024-08-05 | 2.15 | 16.11 B$   |
| 2025-08-05 | 2.15 | 16.11 B$   |

**Analysis:** EPS (Earnings Per Share) has fluctuated. Recent EPS seems to be declining. Revenue has also shown some variation, without a clear upward trend.

**6. Financial Information**

**Revenue and Profitability:**

| Quarter    | Revenue    | Profit Margin |
| :---------- | :--------- | :------------- |
| 2025-06-30 | $15.81B  | 77.50%        |
| 2025-03-31 | $15.53B  | 77.98%        |
| 2024-12-31 | $15.62B  | 75.50%        |
| 2024-09-30 | $16.66B  | 75.51%        |
| 2024-06-30 | $16.11B  | 76.76%        |

**Capital and Profitability:**

| Quarter    | Equity     | ROE    |
| :---------- | :---------- | :----- |
| 2025-06-30 | $48.99B   | 9.04%  |
| 2025-03-31 | $48.34B   | 10.51% |
| 2024-12-31 | $46.31B   | 8.08%  |
| 2024-09-30 | $44.50B   | 7.09%  |
| 2024-06-30 | $43.58B   | 12.52% |

**Analysis:** Revenue has been relatively stable. Profit margins are high. Equity has been growing steadily, but ROE (Return on Equity) has been volatile, with a recent decrease.

**7. Overall Summary and Conclusion**

MRK has significantly underperformed the S&P 500, and its long-term expected return is alarmingly negative. While recent news is positive (particularly the FDA priority review for Keytruda), and analyst consensus is a "Buy," there are several concerning factors:

*   **Underperformance:**  Consistent underperformance vs. the S&P 500.
*   **Negative Expected Return:** A very large negative expected return raises serious concerns about the long-term investment potential.
*   **Fluctuating Earnings:** Recent EPS decline is a cause for concern.
*   **Volatile ROE:** ROE volatility may suggest an inefficient use of funds.

**Recommendation:**

Despite the positive analyst ratings and encouraging news about Keytruda, the significant underperformance, negative expected return, and earnings fluctuations warrant caution. A comprehensive review of MRK's long-term strategy and competitive landscape is needed to justify an investment. It might be better to hold a neutral position.
